Reshape ApS: Financial statements 2023
CVR: 40056173
Source: annual report 2023, Danish Business Authority
01/04/2022 – 31/03/2023
Reshape ApS (CVR 40056173) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 1,968,767 and a net result of DKK -4,638,554 compared with DKK -1,649,207 the year before. Equity in the 2023 report amounted to DKK 26,894,488. The solvency ratio was 95.3%. The company had 10 employees in the financial year.
- Gross Profit
- DKK 1,968,767
- Profit/Loss
- DKK -4,638,554
- Equity
- DKK 26,894,488
- Total Assets
- DKK 28,220,499
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 2 mio. | -4.6 mio. | 26.9 mio. | 10 |
| 2022 | - | -118 t. | -1.6 mio. | 5.5 mio. | 16 |
| 2021 | - | 593 t. | 52 t. | 1.3 mio. | 7 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of June 13, 2023, KPMG P/S has been appointed auditor of Reshape ApS.
About Reshape ApS
Reshape ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Carl-Emil Grøn Fuglesang, Daniel Storgaard and Magnus Nyborg Madsen. The company is owned by Reshape Biotech Inc.. According to the 2026 annual report, the company had an average of 56 employees. In 2026, the company reported a gross profit of DKK 5,310,622 and a net result of DKK -42,643,506 compared with DKK -35,557,856 the year before. Equity in the 2026 report amounted to DKK 75,515,117.